REGENXBIO to Highlight Its Work at Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) is gearing up to engage with investors through participation in prominent investor conferences shortly. This presents a unique opportunity for the company to showcase its advancements in gene therapy and to provide insights into its pipeline.
Key Conference Details
The company will be attending three major conferences that are noteworthy for investors and stakeholders:
UBS Global Healthcare Conference
This conference features a fireside chat scheduled for Wednesday, taking place at 12:30 p.m. PT. Attendees can expect a robust discussion on the future of healthcare and REGENXBIO's strategic directions.
Stifel 2024 Healthcare Conference
Following the UBS conference, REGENXBIO will participate in the Stifel 2024 Healthcare Conference. The company’s discussion is set for Tuesday, at 11:30 a.m. ET. This event will focus on the innovations in gene therapy that REGENXBIO is spearheading.
Piper Sandler 36th Annual Healthcare Conference
Lastly, the company will join the Piper Sandler conference, with a fireside chat on Thursday at 9:30 a.m. ET. Expect in-depth insights on REGENXBIO’s pipeline, which includes groundbreaking therapeutic options.
Accessing Live Presentations
Investors can catch live webcasts of these discussions in the Investors section of REGENXBIO's official website. Additionally, archived versions will be available for approximately 30 days after the live presentations, ensuring that all interested parties can access essential information regarding the company's advancements.
About REGENXBIO Inc.
REGENXBIO is a leading force in the biotechnology sector, dedicated to improving lives through the potential of gene therapy. Established in 2009, the company has made significant strides in developing AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO's robust pipeline includes therapies aimed at treating various rare and retinal diseases. Noteworthy candidates include RGX-202 for Duchenne muscular dystrophy, ABBV-RGX-314 to combat wet AMD and diabetic retinopathy in collaboration with AbbVie, and RGX-121 for MPS II. With thousands of patients benefiting from their AAV Therapeutic technologies, the company is truly pioneering a revolutionary approach to healthcare.
Contacts
For any inquiries regarding corporate communications, please reach out to Dana Cormack, who oversees communications at REGENXBIO. For investor relations inquiries, George E. MacDougall is available to assist potential and current investors.
Frequently Asked Questions
What is the focus of REGENXBIO at these conferences?
REGENXBIO will focus on discussing its gene therapy advancements and updates on its pipeline during the conferences.
Where can I find the live webcasts of the conferences?
The live webcasts can be found in the Investors section of REGENXBIO's official website.
What are some of the products in REGENXBIO's pipeline?
REGENXBIO's pipeline includes treatments like RGX-202 for Duchenne and ABVV-RGX-314 for wet AMD and diabetic retinopathy.
How long will the recorded presentations be available?
The archived webcasts will be accessible for approximately 30 days following the live presentations.
Who can I contact for investor inquiries?
George E. MacDougall handles investor relations and can provide assistance to current and potential investors.